Form 4: PTC Therapeutics Director Jerome Zeldis Exercises Options and Sells Shares
SEC Form 4 Filing
Director Jerome Zeldis exercised stock options and sold shares of PTC Therapeutics on May 22, 2024.
Summary
- On May 22, 2024, Jerome Zeldis, a director of PTC Therapeutics, exercised stock options to acquire 20,000 shares of common stock at a price of $26.42 per share.
- On the same day, Zeldis sold 20,000 shares of PTC Therapeutics common stock at a weighted average price of $38.24, with prices ranging from $38.20 to $38.55.
- Following these transactions, Zeldis directly owns 14,500 shares of PTC Therapeutics common stock.
- Zeldis also continues to hold options to purchase 0 shares of PTC Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions, with no inherent positive or negative sentiment. It simply reports facts.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the buying and selling activities of company directors. It's common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of stock option exercise and share sale. |
| 05/24/2024 | Date of signature on the Form 4 filing. |
| 07/31/2024 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.